Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers

Table 1 Summary of the main characteristics of the studies enrolled in the meta-analysis

Study	Year	Country of origin	Tumor type	Sample size	NNT-AS1 expression		Follow-up months	Detection assay	Clinical stage	Metastasis analysis	Outcome measure	Survival analysis	Cut-off value	NOS	Ref.
Study	Year	Country of origin	Tumor type	Sample size	High	Low	Follow-up months	Detection assay	Clinical stage	Metastasis analysis	Outcome measure	Survival analysis	Cut-off value	NOS	Ref.
Gu, Y et al	2019	China	Cholangiocarcinoma	98	N/A	N/A	60	qRT-PCR	TNM I-III	DM	OS	Multivariate	Mean	8	[20]
Huang, L et al	2019	China	Cholangiocarcinoma	48	27	21	36	qRT-PCR	TNM I-IV	LNM	OS	Univariate	Median	8	[26]
Wu, D et al	2019	China	Bladder cancer	47	24	23	60	qRT-PCR	TNM I-IV	LNM	OS	Univariate	Median	8	[27]
Chen, B et al	2018	China	Gastric cancer	48	27	21	60	qRT-PCR	TNM I-IV	LNM	OS	Univariate	Median	7	[28]
Gu, Y et al	2018	China	Gastric cancer	77	39	38	65	qRT-PCR	TNM I-IV	LNM	OS	Univariate	Mean	8	[29]
Ye, H et al	2018	China	Osteosarcoma	126	63	63	80	qRT-PCR	Enneking IA-III	DM	OS/DFS	Univariate	Median	7	[15]
Li, Y et al	2018	China	Breast cancer	64	32	32	60	qRT-PCR	TNM I-III	N/A	OS	Multivariate	Mean	8	[19]
Lu, Y et al	2017	China	Hepatocellular cancer	42	23	19	50	qRT-PCR	TNM I-IV	LNM	OS	Univariate	Median	7	[18]
Wang, Q et al	2017	China	Colorectal cancer	70	35	35	39	qRT-PCR	TNM I-IV	LNM/DM	OS/PFS	Multivariate	Median	9	[21]
Hua, F et al	2017	China	Cervical cancer	79	40	39	60	qRT-PCR	FIGO Ib-IIIa	LNM	OS	Univariate	Median	8	[30]

DFS disease-free survival, DM distant metastasis, FIGO the International Federation of Gynecology and Obstetrics, HR hazard ratio, LNM lymph node metastasis, N/A not available, NNT-AS1 nicotinamide nucleotide transhydrogenase antisense RNA 1, NOS Newcastle-Ottawa Scale, OS overall survival, PFS progression-free survival, TNM tumor node metastasis

ISSN: 1471-2407